



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Perindopril-d₃ erbumine

Cat. No.:	HY-B0130AS
Molecular Formula:	C ₂₃ H ₄₀ D ₃ N ₃ O ₅
Molecular Weight:	444.62
Target:	NF-κB; STAT; Sirtuin; Angiotensin-converting Enzyme (ACE); Isotope-Labeled Compounds
Pathway:	NF-κB; JAK/STAT Signaling; Stem Cell/Wnt; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Perindopril-d ₃ (erbumine) is deuterated labeled Perindopril (erbumine) (HY-B0130A). Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure ^{[1][2][3][4]} .
In Vitro	<p>Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].</p> <p>Perindopril erbumine (1 μM, 24 h) ameliorates gliosis and blunts decrease induced by LPS (HY-D1056) in AT2R expression in Rat astrocytoma cell line (C6) and murine microglial cell line (BV2)^[2].</p> <p>Perindopril erbumine (1 μM, 24 h) prevents IκBα degradation, NF-κB nuclear translocation and STAT3 activation induced by LPS (HY-D1056) in C6 and BV2^[2].</p> <p>Perindopril erbumine (1 μM, 24 h) ameliorates the imbalance in the release of inflammatory cytokine and blunts the aberrant ROS production and the nitrite release induced by LPS (HY-D1056) in C6 and BV2^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>Perindopril erbumine (0.1 mg/kg, Oral gavage, once a day for five consecutive days) prevents LPS-induced neuroinflammation in rats^[2].</p> <p>Perindopril erbumine (0.42 mg/kg, Oral, once a day for 4 weeks) with Huangqi-Danshen decoction (HDD) (4.7 g/kg, Oral, once a day for 4 weeks) attenuates adenine(HY-B0152)-induced Chronic kidney disease (CKD) in rats^[3].</p> <p>Perindopril erbumine (0.4-1.5 mg/kg, Oral, once a day for 4-24 weeks) has a persistent effect on blood pressure in spontaneously hypertensive rats (SHR)^[5].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Bhat S A, et al. Angiotensin receptor blockade modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation better than angiotensin-converting enzyme inhibition [J]. *Molecular neurobiology*, 2016, 53: 6950-6967.
- [2]. Wei X, et al. Combination of perindopril erbumine and huangqi-danshen decoction protects against chronic kidney disease via sirtuin3/mitochondrial dynamics pathway [J]. *Evidence-Based Complementary and Alternative Medicine*, 2022, 2022.

-
- [3]. Afonso T, et al. Pharmacodynamic evaluation of 4 angiotensin-converting enzyme inhibitors in healthy adult horses [J]. Journal of veterinary internal medicine, 2013, 27(5): 1185-1192.
- [4]. Thybo N K, et al. Dose-dependent effects of perindopril on blood pressure and small-artery structure [J]. Hypertension, 1994, 23(5): 659-666.
- [5]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA